Wells Fargo
KZR

Wells Fargo’s Kezar Life Sciences KZR Stock Holding History

Wells Fargo’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43K Sell
5,796
-40
-0.7% -$260 ﹤0.01% 5505
2025
Q4 		$36.7K Sell
5,836
-10
-0.2% -$58 ﹤0.01% 5646
2025
Q3 		$22.8K Buy
5,846
+100
+2% +$410 ﹤0.01% 5765
2025
Q2 		$26.3K Buy
5,746
+43
+0.8% +$184 ﹤0.01% 5712
2025
Q1 		$27.8K Sell
5,703
-474
-8% -$2.88K ﹤0.01% 5601
2024
Q4 		$41.5K Sell
6,177
-1,639
-21% -$12.2K ﹤0.01% 5549
2024
Q3 		$60.4K Sell
7,816
-135
-2% -$814 ﹤0.01% 5275
2024
Q2 		$47.7K Sell
7,951
-1,019
-11% -$7.75K ﹤0.01% 5313
2024
Q1 		$80.9K Sell
8,970
-612
-6% -$5.58K ﹤0.01% 5020
2023
Q4 		$90.8K Sell
9,582
-2,066
-18% -$18.2K ﹤0.01% 4967
2023
Q3 		$139K Buy
11,648
+1,389
+14% +$24.6K ﹤0.01% 4585
2023
Q2 		$251K Buy
10,259
+245
+2% +$6.38K ﹤0.01% 4441
2023
Q1 		$313K Buy
10,014
+5,805
+138% +$336K ﹤0.01% 4157
2022
Q4 		$296K Sell
4,209
-448
-10% -$33.2K ﹤0.01% 3956
2022
Q3 		$400K Sell
4,657
-4,014
-46% -$390K ﹤0.01% 3828
2022
Q2 		$717K Sell
8,671
-3,186
-27% -$281K ﹤0.01% 3513
2022
Q1 		$1.97M Sell
11,857
-3,055
-20% -$438K ﹤0.01% 3317
2021
Q4 		$2.49M Sell
14,912
-10,359
-41% -$1.17M ﹤0.01% 3265
2021
Q3 		$2.18M Buy
25,271
+1,079
+4% +$71.4K ﹤0.01% 3593
2021
Q2 		$1.31M Sell
24,192
-1,464
-6% -$83.1K ﹤0.01% 4023
2021
Q1 		$1.53M Sell
25,656
-5,765
-18% -$337K ﹤0.01% 3929
2020
Q4 		$1.64M Buy
31,421
+8,573
+38% +$477K ﹤0.01% 3632
2020
Q3 		$1.1M Sell
22,848
-7,842
-26% -$375K ﹤0.01% 3783
2020
Q2 		$1.59M Buy
30,690
+23,519
+328% +$1.19M ﹤0.01% 3446
2020
Q1 		$312K Sell
7,171
-1,599
-18% -$65K ﹤0.01% 4393
2019
Q4 		$352K Buy
8,770
+4,577
+109% +$141K ﹤0.01% 4624
2019
Q3 		$138K Buy
4,193
+1,105
+36% +$53.4K ﹤0.01% 5166
2019
Q2 		$238K Buy
3,088
+2,321
+303% +$361K ﹤0.01% 4873
2019
Q1 		$136K Buy
767
+509
+197% +$100K ﹤0.01% 5012
2018
Q4 		$61K Buy
258
+25
+11% +$6.11K ﹤0.01% 5458
2018
Q3 		$50K Buy
+233
New +$40.7K ﹤0.01% 5592

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Wells Fargo's KZR Position: Q1 2026 in Review

Wells Fargo reduced its Kezar Life Sciences (KZR) stake by 0.69% in Q1 2026, selling an estimated $260 and leaving 5,796 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #5505.

Wells Fargo first reported a position in KZR in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.49M in Q4 2021. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Wells Fargo held 5,796 shares of Kezar Life Sciences worth $43K as of Q1 2026.
  • Wells Fargo sold 40 Kezar Life Sciences shares in Q1 2026, an estimated $260.
  • Kezar Life Sciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5505 holding.
  • Wells Fargo first reported a position in Kezar Life Sciences in Q3 2018 and has held it in 31 quarters since.
  • Wells Fargo's Kezar Life Sciences position peaked at $2.49M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.